WO1994028871A1 - Implant stimulated cellular immunity - Google Patents

Implant stimulated cellular immunity Download PDF

Info

Publication number
WO1994028871A1
WO1994028871A1 PCT/US1994/006394 US9406394W WO9428871A1 WO 1994028871 A1 WO1994028871 A1 WO 1994028871A1 US 9406394 W US9406394 W US 9406394W WO 9428871 A1 WO9428871 A1 WO 9428871A1
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
implant
cells
cell
pathogen
Prior art date
Application number
PCT/US1994/006394
Other languages
French (fr)
Inventor
Robert J. Leonard
Original Assignee
Endocon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocon, Inc. filed Critical Endocon, Inc.
Priority to AU71012/94A priority Critical patent/AU7101294A/en
Publication of WO1994028871A1 publication Critical patent/WO1994028871A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Definitions

  • This invention relates to methods and products for stimulating vivo cytotoxic T lymphocytes capable of killing cells infected with a pathogen.
  • HIV human immunodeficiency virus
  • the immune system is adapted among other things to protect mammals against infectious disease. It is comprised of cells derived from totipotent stem cells, and includes lymphocytes, monocytes/macrophages and granulocyte ⁇ .
  • the lymphocytes are composed principally of two major groups: the thymus associated T cells and the antibody producing B cells. In birds, these antibody producing cells clearly originate in the bur ⁇ a, thus, B cells. It is not at all clear that such a system exists in mammals.
  • B cell is utilized simply by convention.
  • T cells represent the most complex subclas ⁇ in view of the range of specialized functions assumed by distinct subgroups. Certain T cells act to regulate T and B cell function by the production of cytokines and by contact. Other T cells can terminally differentiate into cytotoxic T lymphocytes (CTLs), which are responsible for cell-mediated immunity by lysing pathogen-infected cells.
  • CTLs cytotoxic T lymphocytes
  • CTLs are of two lineage ⁇ , characterized by the nature of the markers which they carry on their cell surface. These markers can be CD4 or CD8, the most predominant variety.
  • the conditions required to cause a CD8 or CD4 cell to differentiate into a CTL are not well understood and are only now beginning to be elucidated. These conditions are complex and differ for CD8 and CD4 cells; for either cell type, various intercellular message molecules (cytokines) are involved. Cytokines play a major role in all forms of immunity and are at the heart of the inflammatory response. Since cytokines are so significant to the functional properties as well as specific differentiation of cell types —including whether or not a T cell expresses CD4 or CD8— the use of cytokines as a therapeutic modality has been attempted, unfortunately with only limited success.
  • Macrophages arise from specific monocyte stimulation and represent one of the most versatile cells of the immune system, able to lyse and/or engulf foreign bodie ⁇ (bacteria, viru ⁇ es, etc.) and scavenge toxins and tumor cells. Macrophages respond to and are the source of numerous cytokines, including cytokine ⁇ that are responsible for T cell differentiation. Macrophages also present antigen to both CTLs and B cells in connection with stimulating cell-mediated immunity or inducing a humoral antibody response, respectively.
  • One approach to the treatment of infectious disease is the use of vaccines.
  • Vaccines have been very successful in treating some infections, but somewhat ineffective in treating other ⁇ . This is perhaps due to the combination of the interaction between two complex systems, the host's immune system and the pathogen's system of replication.
  • Antigens were physically entrapped in or chemically cross-linked to the interior of microporous microparticles.
  • the micropores were of a size that would permit cellular infiltration.
  • Agents for recruiting lymphocytes to the microparticles were suggested for inclusion in the microparticles.
  • One recent approach to treating a subject infected with the human immunodeficiency virus was to remove a sample of the subject's lymphocytes and stimulate them in vitro in the presence of an antigen associated with a specific pathogen. This produced a sub-sample of cells which was enriched for cytotoxic T lymphocyte ⁇ that recognized the antigen.
  • the sub-sample of cytotoxic T lymphocytes was shown to be capable of lysing pathogen-infected cells of the subject. Accordingly, the sub-samples were administered to the subjects from which they were derived to treat the subject for the infectious disease.
  • CD8 T cells recognize antigenic peptide ⁇ pre ⁇ ented by MHC class I molecules and that for some infections, only a small number of peptides ( "immuno-dominant peptides") are capable of initiating the terminal differentiation of a CD8 cell into a cytotoxic T lymphocyte. If further was reported that cytotoxic T lymphocytes ⁇ pecific for ⁇ uch immuno-dominant peptide ⁇ are subject-specific and dominate the lytic response. Accordingly, when a subject's cytotoxic T lymphocyte ⁇ were removed for in vitro enrichment as de ⁇ cribed above, a panel of peptide ⁇ wa ⁇ used to ensure that the appropriate antigen wa ⁇ present for stimulating the subject-specific cytotoxic T lymphocyte response.
  • the invention provide ⁇ method ⁇ and products for stimulating in vivo cell-mediated immunity against pathogen-infected cells. It involves forming a local, chronic, inflammatory site and presenting an antigen associated with a pathogen at that ⁇ ite at a level appropriate for ⁇ timulating cell-mediated immunity against cells infected with the pathogen.
  • Condition ⁇ are created at the local inflammatory site which favor the terminal di ferentiation of T cells into cytotoxic T lymphocytes. T cell ⁇ thus are continually recruited and expanded, thereby maximizing the potential for a vigorous cytotoxic response against the pathogen infected cells.
  • novel sustained-released devices are provided.
  • the devices are solid, immunogenic implants that induce, when implanted subcutaneously, the formation of a subcutaneous fibrous capsule defining a chronic inflammatory site.
  • the implant contains an antigen associated with a pathogen.
  • the implant i ⁇ con ⁇ tructed and arranged to pre ⁇ ent the antigen for an extended period of time at a level appropriate for stimulating cell-mediated immunity, but at a level that does not induce tolerance.
  • the implant can be free of materials that suppress the immune response.
  • the implant contain a cytokine or a combination of cytokines for stimulating cell-mediated immunity.
  • the implant includes the cytokines interleukin 2, interleukin 4, interleukin 8, interleukin 12 and interferon ⁇ , and it is preferred that the implant be constructed and arranged to deliver the cytokine for the same period of time that the antigen is being presented.
  • the implant also can contain an agent for ⁇ uppre ⁇ sing the conversion of macrophages into foam cells, and preferably the agent i ⁇ an antioxidant.
  • a subcutaneous fibrous capsule defining a chronic, local, inflammatory site is created in the ⁇ ubject by implanting ⁇ ubcutaneously a foreign body.
  • An antigen associated with the pathogen then is presented continuously at a level appropriate for stimulating cell-mediated immunity, but at a level that does not induce tolerance.
  • the antigen can be delivered using the devices described above.
  • the invention is particularly useful in the treatment of a subject infected with HIV.
  • the chronic presentation of low do ⁇ es of antigen in the environment of the fibrous capsule can produce a cytotoxic T cell response directed to HIV infected cells.
  • a cytotoxic T cell re ⁇ pon ⁇ e i ⁇ believed to be crucial in combating HIV infection and in preventing or arresting the development of Autoimmune Deficiency Syndrome (AIDS) .
  • AIDS Autoimmune Deficiency Syndrome
  • the invention involves forming a discrete, localized site of chronic inflammation, and using this site of inflammation as a local 'factory' for the production of cytotoxic T lymphocytes (CTLs) that will lyse cells infected with a specific pathogen.
  • CTLs cytotoxic T lymphocytes
  • the expanded set of CTLs specific for a pathogen can erradicate or prevent the development of infection and al ⁇ o can be used to treat or arrest the development of cancers associated with infection.
  • a complex cellular response takes place which can result in the implanted object being encapsulated by a dense, fibrous capsule or compartment.
  • the cap ⁇ ule is often characterized by new capillarie ⁇ of both blood ves ⁇ els and lymphatics. It is believed that this process begins with the chemotaxis of neutrophils and monocyte/macrophages to the site of "injury", probably enlisted by the presence of platelet derived growth factor (PDGF) and granulocyte/macrophage colony stimulating factor (GM-CSF) . Macrophages apparently coat the object while simulataneou ⁇ ly stimulating fibroblasts to begin constructing the fibrou ⁇ "wall".
  • PDGF platelet derived growth factor
  • GM-CSF granulocyte/macrophage colony stimulating factor
  • the capsule i ⁇ highly structured, consi ⁇ ting of an inner lumen which can be lined with a layer of loo ⁇ e cellular material, a middle fibrous layer, and an outer loose connective tissue layer.
  • the middle layer contains we11-developed blood ves ⁇ el ⁇ and lymphatics and can be on the order, for example, of one half to thirty millimeters in thickness (thousand ⁇ of cells in thickness).
  • the cellular compartment contains numerous round cells, macrophages and fibroblasts. The macrophage ⁇ e ⁇ entially coat the foreign body.
  • local inflammatory microenvironment pertains to chronic, nonpathogenic, tissue responses characterized by: (1) macrophage stimulation and chemotaxis; (2) fibroblast stimulation and collagen deposition to form a dense fibrous capsule; and (3) development and infiltration of neovasculature (angiogenesis) and lymphatics. Not all foreign body respon ⁇ es and granulomas are the same as they relate to the relative pre ⁇ ence of these components.
  • chemotaxis attracts lymphocytes and macrophages to the site of inflammation within the vascularized fibrous capsule. Since the implant appears to remain coated with macrophages throughout, it is believed that the environment is particularly ⁇ uited for antigen pre ⁇ entation to circulating lymphocytes and the creation of cytotoxic T lymphocytes.
  • B cell stimulation is enhanced significantly. It may be that in certain circum ⁇ tances, the B cell response is actually suppressed. If desired, the B cell respon ⁇ e can be suppressed by including B cell suppressing agents in the implant.
  • this local microenvironment also can be manipulated by including cellular regulator ⁇ in the implant.
  • Such cellular regulator ⁇ previou ⁇ ly were u ⁇ ed to affect the development of the fibrou ⁇ capsule and its vasculature, thereby affecting the release-kinetics of drugs contained in the implant.
  • the present invention is designed to exploit this same local, inflammatory microenvironment for the purpose of generating a cell-mediated immune response to a pathogen- ⁇ pecific antigen.
  • This local inflammatory microenvironment is particularly suited for recruiting the components of the cell-mediated immune system (e.g. macrophages, T-lymphocytes) and for creating an environment well-suited for the processing and presentation of antigens and the proliferation of CTLs.
  • the invention involves presenting an antigen associated with a pathogen within this microenvironment at a frequency or "dose" that is appropriate for stimulating cell-mediated immunity, but is low enough such that tolerance is not induced.
  • dose a frequency or "dose” that is appropriate for stimulating cell-mediated immunity, but is low enough such that tolerance is not induced.
  • agents for inducing a vigorous CTL response may be introduced into this microenvironment (in addition to such agents as occur naturally within the local microenvironment).
  • the invention is useful in connection with stimulating cell-mediated immunity in mammals infected with an intraceUular pathogen such as a virus, bacterium, fungus or protozoan.
  • intraceUular pathogen such as a virus, bacterium, fungus or protozoan.
  • IntraceUular pathogen means a disease-causing organism which reside ⁇ , during at least part of its life cycle, within a host cell.
  • Viruses include but are not limited to those in the following families: picornaviridae; caliciviridae; togaviridae; flaviviridae; coronaviridae; rhabdoviridae; filoviridae; paramyxoviridae; orthomyxoviridae; bunyaviridae; arenaviridae; reoviridae; retroviridae; hepadnaviridae; parvoviridae; papovaviridae; adenoviridae; herpesviridae; and poxyviridae.
  • Bacteria include but are not limited to: P. aeruginosa; E. coli; kleb ⁇ iella; serratia; pseudomonas; B. fragili ⁇ ; P. cepacia; acinetobacter; N. gonorrhoeae; S. epider i ⁇ ; E. faecalis; S. pneumoniae; S. aureus; haemophilus; neisseria; N. meningitidis; bacteroides; citrobacter; branhamella; salmonella; shigella; S. pyogene ⁇ ; proteu ⁇ ; clostridium; erysipelothrix; le ⁇ teria; L.
  • Fungi include but are not limited to: cryptococcus neoformans; blastomyces dermatitidis; ajellomyce ⁇ dermatitidi ⁇ ; histoplasma capsulatum; coccidioide ⁇ immiti ⁇ ; Candida, including C. albican ⁇ , C. tropicalis, C. parapsilo ⁇ is, C. guilliermondii and C. krusei; aspergillu ⁇ , including A. fumigatus, A. flavu ⁇ and A.
  • Human immunodeficiency virus including, without limitation, HIV-l and HIV-2
  • human T cell leukemia virus including, without limitation, HTLV-I and HTLV-II
  • herpes virus including, without limitation, Herpes simplex type 1 and type 2, Herpes zoster, and cytomegalovirus as well as epstein-barr viru ⁇
  • papillomavirus including, without limitation hepati ⁇ i ⁇ A, B and C
  • feline leukemia viru ⁇ micobacteria (including, without limitation, M. tuberculo ⁇ is and M.
  • the invention is particularly useful when a T cell respon ⁇ e i ⁇ important in treating or preventing an infection by a pathogen. Most preferred is treatment or prevention of infection by human immunodeficiency virus.
  • the antigen selected for use in connection with the present invention will depend upon the particular disea ⁇ e being treated. It may be any antigen a ⁇ sociated with the pathogen.
  • the antigen can be a plurality of antigens or a single, defined epitope. It can be whole and/or attenuated viru ⁇ , bacterium, fungu ⁇ or protozoan. It can be any portion thereof, isolated according to procedures well known to those of ordinary skill in the art. For example, it can be a component of a pathogen isolated by disrupting the pathogen and isolating the component. It al ⁇ o can be produced by mutation and/or recombinantly a ⁇ a mutant pathogen.
  • It can be whole protein, fu ⁇ ion protein, peptide, or part of a vector ⁇ uch as part of a vaccinia vector. It further can be produced synthetically, such a ⁇ a peptide ⁇ ynthe ⁇ ized de novo, or it can be derived from a related organi ⁇ m (e.g. Bacillus Calmette-Guerin (BCG) in the case of tuberculosis) .
  • BCG Bacillus Calmette-Guerin
  • the invention in its broadest aspect is not intended to be limited by the selection of the particular antigen or by its mode of preparation. Those of ordinary skill in the art will have available to them well characterized antigens previously used, for example, as vaccines for treating the various conditions di ⁇ cussed herein.
  • an "antigen associated with a pathogen” is any antigen that is capable of inducing a cell-mediated immune response and capable of being recognized by a cytotoxic T cell a ⁇ part of the pathogen or a cell infected with the pathogen.
  • many antigenic components have been well characterized and cloned. Some antigenic components include nuclear materials which are expres ⁇ ed on the ⁇ urface of cells infected by the human immunodeficiency virus. Other antigenic components include peptides. The following i ⁇ a list of epitopes reported to be capable of ⁇ timulating CTL ⁇ .
  • peptides may be subject specific. The subject then may need to be tested in advance of treatment according to the present invention to determine the identity of peptides most u ⁇ eful for stimulating cellular immunity.
  • Such a procedure has been developed for subject ⁇ infected with human immunodeficiency virus, and is reported in PCT application PCT/US91/06441 , publication no. WO92/04462, published March 19, 1992.
  • a peptide fragment of influenza matrix protein shown to be restricted by HLA-A2 may be used: TKGILGFUFTLTV.
  • This peptide presented by self-MHC, has been shown to induce an increase in CTL proliferation Jj vitro in the presence of a combination of interleukin-12 and low-dose interleukin-2 ( ⁇ ee M. Bertagnolli, B-Y Lin, D. Young and S. Herrmann, IL-12 Augment ⁇ Antigen-Dependent Proliferation of Activated T-lymphocytes, J. Immun. , V. 149, 3778-3783, No. 12, 12/15/92).
  • interleukin-12 and low-dose interleukin-2 ⁇ ee M. Bertagnolli, B-Y Lin, D. Young and S. Herrmann, IL-12 Augment ⁇ Antigen-Dependent Proliferation of Activated T-lymphocytes, J. Immun. , V. 149, 3778-3783, No. 12, 12/15/92.
  • Cytokines may be delivered to the microenvironment and used to induce CTL proliferation.
  • the ⁇ e introduced cytokine ⁇ will augment the stimulatory effect of the cytokine ⁇ occurring naturally in the microenvironment of the fibrou ⁇ cap ⁇ ule.
  • Cytokines are factors that ⁇ upport the growth and maturation of cell ⁇ , including lymphocytes. Important to the invention herein is activating those cells re ⁇ ponsible for cell-mediated immunity and the generation of CTLs. Cytokines are known to participate in such activation.
  • cytokines known to the inventor.
  • T-cells T-cells; induction of macrophages to make cytokines
  • IL-2 T-cell Activates killer cells
  • T cells IL-4 T-cell Growth, activation of T cells IL-6 Macrophages Growth of eo ⁇ inophil ⁇ IL-7 Stromal cells Growth of T cells
  • TNF-alpha Macrophage ⁇ Tumor cytotoxicity TNF-beta T-cells Activates cytokine production
  • IFN-gamma T-cells Activates macrophages Growth Factors
  • Platelet-derived growth factor Platelets Epidermanal growth factors Transforming growth factor Macrophages Fibroblast growth factor
  • IL-2, IL-4 and IL-12 for activating T cells
  • IL-8 for chemotactic recruitment of T cells
  • interferon ⁇ for activating macrophages.
  • the preci ⁇ e amount ⁇ can be determined without undue experimentation.
  • the thre ⁇ hold amount ⁇ of cytokine ⁇ to achieve a particular re ⁇ ult have been tested in the art both in vivo and _in vitro.
  • the maximum amounts may be determined for achieving the highe ⁇ t level ⁇ of antigen-specific CTLs by formulating implants and te ⁇ ting for the pre ⁇ ence of CTLs. It will be understood, however, that practically any amount, no matter how small, of the preferred cytokines should be useful in promoting the differentiation of precursor T cells into CTLs. It further will be understood that the art teaches that low dose ⁇ of IL-2 with IL-12 are particularly useful in stimulating the production of CTLs (see M. Bertagnolli, id). It is believed that cytokines present in the following ranges will be quite suitable for achieving the purposes of the invention.
  • IL-2 10 picograms to 10 nanograms presented daily.
  • IFN 10 picogram ⁇ to 10 nanogram ⁇ pre ⁇ ented daily.
  • the antigen ⁇ are presented subcutaneously as solid aggregate ⁇ .
  • a " ⁇ olid aggregate” a ⁇ used herein means an article of the type that can continue to present at its surface, over an extended period of time, an agent when implanted in vivo.
  • Such devices can be constructed entirely of the agent itself, such as a totally melted and recrystallized pellet of antigen. They al ⁇ o can be con ⁇ tructed of the agent together with a bioerodible excipient ⁇ uch a ⁇ chole ⁇ terol . They further can be contained in a nonerodible matrix ⁇ uch a ⁇ a ⁇ ilastic matrix.
  • the device is capable of pre ⁇ enting the agents, i.e.
  • the solid aggregate devices useful herein thus can present continuously very ⁇ mall amounts of antigen for periods from two months to two years or more.
  • the level of antigen present at the surface of the solid aggregate and taken up by the macrophages per day preferably is less than fifty micrograms per day, in order to prevent tolerance and most preferably is in the nanogram or even picorgram range.
  • Extremely low level ⁇ of presentation are pos ⁇ ible becau ⁇ e the conver ⁇ ion of T cell ⁇ into CTLs occurs in the local microenvironment of the fibrous capsule.
  • the implant is coated entirely with macrophages in the lumen of the capsule, antigen is said to be presented, not released. Free antigen in the blood stream may not even be detectable, since macrophages preferably are binding all antigen within the cap ⁇ ule.
  • the capsule is intended to create an environment rich in cells, cytokines and antigen for stimulating within the capsule the desired immune respon ⁇ e.
  • Thi ⁇ differ ⁇ from the prior art which doe ⁇ not teach implants containing antigen that form such cap ⁇ ule ⁇ and which seek principally to produce a humoral response, and/or action at a distance.
  • IL-2 tends to prevent the induction of anergy in T cells.
  • CD28 stimulation by CD28 agonists including by anti-CD28 antibodies or fragments thereof tend to prevent the induction of anergy.
  • higher doses of antigen may be presented in the presence of such substances without resulting in tolerance.
  • CD8 cells have been reported to respond to peptides, not proteins. Therefore, if the antigen is only whole protein, it is pos ⁇ ible that only CD4 cell ⁇ will be stimulated. On the other hand, it has been reported that CD8 cells will respond only to particular subject-specific, immunodominant peptides (See PCT publication no.
  • WO92/04462 it may be desirable to prescreen a subject to identify those peptides to which the subject will respond maximally if using only peptide ⁇ as an antigen. Nevertheless, the environment of the fibrous capsule may be ⁇ uch as to degrade protein, and CD8 cells still may be activated even when whole protein i ⁇ delivered via the implant. It also will be understood by those of ordinary skill in the art that CD8 cells and CD4 cells respond to different cytokines and signals. Therefore, the antigen selected may also determine the accessory molecules presented with the antigen, such a ⁇ cytokines or other signalling molecules.
  • INF ⁇ may be included in the implant to activate macrophages for presenting antigen.
  • Other materials also may be added to enhance the environment relative to macrophage or T cell activation.
  • oxidated LDL can stimulate macrophages to become foam cells.
  • the fibrous capsule define ⁇ a chamber that contain ⁇ the implant. Surrounding the implant and within the chamber are a variety of cells, including both macrophages and foam cell ⁇ . Macrophages are the precursors of foam cells and are activated to become foam cells by a variety of mechanisms. The most common mechani ⁇ m i ⁇ the interaction of a receptor on the macrophage with oxidated low-density lipoprotein (oxLDL) .
  • oxLDL oxidated low-density lipoprotein
  • the oxLDL is produced by oxidizing low-density lipoprotein, and it has been reported that such oxidation is as ⁇ ociated with ⁇ ite ⁇ of chronic inflammation. In some in ⁇ tances, it may be desirable to prevent such activation to maintain the macrophage ⁇ in a state that is optimal for antigen pre ⁇ entation to T cells. IL-2 is believed to be one such agent. Activation also can be reduced by preventing the formation of oxLDL in the environment of the fibrous capsule. This can be achieved by continuously releasing an anti-oxidant into the environment of the inflammatory site. Anti-oxidant ⁇ include vitamin E, butylated hydroxytoluene, etc.
  • a ⁇ will be under ⁇ tood by those of ordinary skill in the art, virtually any molecule that participates in the conversion of a T cell to a CTL may be pre ⁇ ented at the ⁇ ite of inflammation in accordance with this invention. Many such molecules are known to those of skill in the art, including, without limitation, anti-CD3 antibody and in particular solid phase anti-CD3 antibody, phorbol esters, aloe antigen, B7 and the like.
  • the implants of the invention also may include adjuvants for enhancing the CTL re ⁇ ponse.
  • the implants of the invention may be used prophylactically or therapeutically. When used prophylactically, they typically are given to a subject that is at risk of being infected by a pathogen. When used therapeutically, they typically are given to a subject that is known to have or that is su ⁇ pected of having developed an infection by a pathogen.
  • a subject means a human, primate, horse, cow, sheep, goat, pig, dog, cat or rodent.
  • the preferred sustained release devices are solid, immunogenic, subcutaneous implants that induce the formation of a fibrous capsule defining a chronic inflammatory site.
  • solid implant it is meant solid enough to permit the formation of a dense fibrous capsule ⁇ urrounding the implant prior to substantial dissipation or degradation of the implant.
  • Suitable implants for use in connection with the invention are compressed pellets wherein an antigen, alone or together with an excipient, is compres ⁇ ed under high pre ⁇ ure into a solid implant.
  • a preferred implant is a nonpolymeric ⁇ y ⁇ tem comprising a fused pellet.
  • an antigen, a carrier, or both are melted and recrystallized to form a crystaline matrix of the antigen and/or nonpolymeric carrier.
  • both the antigen and carrier are melted and recrystallized.
  • only the carrier is melted and recrystallized, thereby capturing the antigen in the crystaline matrix of the carrier.
  • a partially fused pellet is particularly suitable for the delivery of proteins or peptides whose conformation and properties might be compromised if heated to their melting temperature.
  • a carrier having a lower melting temperature than the peptide or protein is heated to the melting point of the carrier, and then recrystallized to form a matrix encapsulating the peptide or protein.
  • Stearols are particularly suited for melting and recrystallization.
  • various cholesterol-type compounds including cholesterol acetate may be used.
  • Compounds such as palmitic acid also may be used.
  • the particular methods for forming fused pellets are disclosed in U.S. patent nos. 4,748,024, 4,892,734 and 5,039,660 (all to Leonard), the entire disclosure ⁇ of which are incorporated herein by reference.
  • cellular regulators are combined in a matrix with a bioerodible polymer, such as poly-DL lactide or glycolyde, as a sheath around a core implant including the antigen.
  • a bioerodible polymer such as poly-DL lactide or glycolyde
  • the sheath is formed so as to gradually erode, releasing the cellular regulator and preparing the tissue environment for presentation of the antigen contained in the core.
  • These regulators would be released early and for the time period of formation of the fibrous capsule.
  • the sheath contains a cellular regulator, the sheath or a complete coating can be used to delay the presentation of antigen until a dense fibrous capsule has been formed.
  • the antigen also may be presented in polymeric ⁇ y ⁇ tems.
  • a polymeric system consist ⁇ of matrice ⁇ of polymer ⁇ combined with the antigen.
  • Such system ⁇ include system ⁇ in which the antigen is distributed in or covalently attached to a biodegradable polymer matrix.
  • Biodegradable polymers that have been used in such system ⁇ include hydroxycarboxylic acids, especially lactic acid and glycolic acid. Cholesterol and ethylene vinyl acetate copolymers have al ⁇ o been u ⁇ ed. See, for example, U.S. Patent No. 4,591,496 i ⁇ ued to Cohen et al . , which describes a polymeric system consi ⁇ ting of mixing a drug and a polymer, e.g. ethylene-vinyl acetate copolymer powder ⁇ , below the gla ⁇ tran ⁇ ition temperature of the polymer, and compressing the mixture at a temperature above the transition point.
  • Bioerodible polymers include hydroxycarboxylic acids, especially lactic acid and glycolic acid, polycaprolactone and copolymers thereof.
  • variou ⁇ proportion ⁇ of lactide and glycolyde can be employed, ⁇ uch as 50/50, 65/35, 75/25, and 85/15 percent weight ratios of poly (DL-lactide-co-glycolide) .
  • substantially 100% weight percent poly (DL-lactide) , poly (L-lactide), and polyglycolide can be used.
  • Bioerodible polymers of this type are obtained from Birmingham Polymers, Inc., Birmingham, Alabama 35222.
  • Copolymers of gluconic acid and ethyl-L-glutamic acid and other polypeptide ⁇ can be u ⁇ ed, as well as poly(orthoe ⁇ ters) (Choi et a]. . , U.S. Patent No. 4,093,709) and poly(orthocarbonate) (Schmitt, U.S. Patent No. 4,346,709).
  • poly(acrylate) materials can be employed, such as copolymers of acrylic and methacrylic acid esters or copolymers of methacrylic acid and methyl methacrylate (Sothmann et al . , U.S. Patent No. 4,351,825).
  • Cholesterol and ethylene vinyl acetate copolymers can also be used. See for example, U.S. Patents 4,452,775 (J.S. Kent) and 4,591,496 (J.M. Cohen et al..), respectively.
  • a polymeric matrix If a polymeric matrix is employed, it must be fashioned to be a "solid aggregate" as defined herein.
  • the matrices of the prior art typically were used for releasing circulating amounts of antigen for inducing a B-cell respon ⁇ e. They al ⁇ o typically were porou ⁇ , permitting ti ⁇ ue infiltration and/or were erodible or nonimmunogenic to an extent where a den ⁇ e fibrou ⁇ cap ⁇ ule did not form.
  • a dense fibrous capsule can form as a result of implanting a solid, immunogenic foreign body and that ⁇ uch a cap ⁇ ule is desirable for presenting antigen, those of ordinary ⁇ kill in that art will be able to manufacture solid, immunogenic implants from polymer matrices.
  • inert materials are made of inert materials.
  • inert refers to implants that are not eroded or otherwise structurally compromised when implanted.
  • Exemplary materials include polytetrafluoroethylene (Teflon®), plastic, silicone or ceramic materials.
  • the invention also provides methods and product ⁇ for treating cancer.
  • Certain viruses are associated with cancer and are expressed on -neoplastic cells, but not normal cells. These include hepatisis B, Epstein Barr virus and human pampalloma virus.
  • the methods and products of the invention thus are adapted for stimulating cell-mediated immunity against viral cancer antigens for the purpo ⁇ e of producing cytotoxic T cell ⁇ again ⁇ t neopla ⁇ tic cells.
  • viral antigens are known to those of ordinary skill in the art.
  • the best characterized cancers include melanomas, ovarian cancers and renal cancers.
  • a solid implant for stimulating cell-mediated immunity against influenza virus A solid implant for stimulating cell-mediated immunity against influenza virus.
  • the peptide fragment of influenza matrix protein is homogeneously distributed and captured in a matrix of a melted and recrystallized nonpolymer carrier.
  • the carrier powdered cholesterol acetate obtained from Sigma Chemical Co. of St. Louis, MO., has a lower melting point than the influenza peptide and is ⁇ elected ⁇ o that when a homogeneou ⁇ mixture of the chole ⁇ terol acetate and peptide i ⁇ heated, a partial melt may be formed with substantially all of the carrier melting and substantially all of the peptide not melting. The partial melt then is allowed to cool, with the cholesterol acetate recrystallizing to form the hardened pellet and capture the influenza peptide.
  • Pellet ⁇ of the foregoing type are formed a ⁇ described in U.S. patent 5,039,660, the entire disclosure of which is incorporated herein by reference. Briefly, fluorocarbon tube ⁇ that are ⁇ traight cylinder ⁇ having an inner diameter of 0.095 inches, an outer diameter of 0.135 inches and a length of 0.625 inche ⁇ are provided. Such tubing i ⁇ ⁇ old under the name of Teflon-TFE, Norton Chempla ⁇ t, Inc., of Wayne, N.J. Next, the powdered chole ⁇ terol acetate and the influenza peptide are combined in approximate proportion ⁇ of 10% peptide and 90% cholesterol acetate (weight/weight) .
  • the mixture is dispensed into the fluorocarbon tube in an amount such that when dried, the remaining powder equals 2ml in depth after a first compression phase.
  • Approximately 20g of powder in the form of a paste is added to the tube using a pipette. A vacuum force then is applied acros ⁇ the filter ⁇ heet to evaporate the solvent.
  • Accurate dispen ⁇ ing of the ⁇ tarting materials can be achieved by forming the paste which is made from a powdered mixture of the starting material ⁇ and a liquid ⁇ uch as ethyl alcohol.
  • the alcohol may be dried out of the starting materials after dispensing, utilizing, for example, a standard vacuum oven.
  • a pa ⁇ te the material can be dispensed accurately from a standard, automated device such as a micropipeter.
  • the pa ⁇ te may be manufactured to have the flow characteristics of ordinary toothpaste.
  • the tube is plugged with a 3mm piece of Teflon beading, and the dry mixture then is compressed against the plug, using a steel pin inserted into the end of the tube opposite the plug.
  • the plug end is held against a solid surface to prevent the plug from being expelled from the tube.
  • the degree of compression corresponds to about 2200 p.s.i. for three seconds.
  • the tube containing the compressed dry mixture then is transferred on the pin to an oven preheated to 180°F. The tube is exposed to this environment for 30 seconds.
  • the tube then is removed from the oven and is compressed by hand at about 150 p.s.i. for about six second ⁇ a ⁇ the partially-melted material cools and recrystallize ⁇ to form a hardened pellet.
  • Pellets of the foregoing type are commercially available from Endocon, Inc., Walpole, MA, U.S.A.
  • One method of administering the implant is using an injector of the type described in U.S. patent 4,846,793, the entire disclosure of which is incorporated herein by reference. Such injectors also are sold by Endocon, Inc.
  • the formed pellet is implanted subcutaneously in a mammal and a fibrous capsule surrounding the implant is permitted to form.
  • a sample of peripheral blood i ⁇ collected and te ⁇ ted for the pre ⁇ ence of cytotoxic T cells active against cell ⁇ infected with influenza virus.
  • Procedures for collecting blood and testing for the presence for influenza-specific cytotoxic T cells are well known to those of ordinary skill in the art.
  • a solid implant for stimulating cell-mediated immunity against influenza viru ⁇ the implant containing cytokines.
  • Example I Same a ⁇ Example I, except that the mixture include ⁇ 10% influenza matrix peptide, 88% chole ⁇ terol acetate, 0.8% Interleukin-12, 0.4% Interleukin-2, 0.4% Interleukin-8, 0.2% Interleukin-2 and 0.2% Interferon ⁇ .
  • Example IV The procedure of Example I is followed, except that 90% cholesterol acetate and 10% of an HIV-CTL epitope are used as starting materials.
  • Example IV The procedure of Example I is followed, except that 90% cholesterol acetate and 10% of an HIV-CTL epitope are used as starting materials.
  • Example II The same as Example I, except that 95% cholesterol acetate and 5% of a subject-specific immunodominant peptide are used as starting materials.
  • the subject-specific immunodominant peptide is identified as de ⁇ cribed in U.S. patent application serial no. 07/578,828, filed September 6, 1990, the entire disclosure of which is incorporated herein by reference.
  • Example II The same as Example I, except that 80% cholesterol acetate, 15% influenza peptide, 4% Interleukin-12 and 1% Interleukin-2 are used as starting material ⁇ .
  • Example II The same as Example I, except that 96% cholesterol acetate, 2% influenza peptide, 1% Interleukin-12, 0.5% Interleukin-2 and 0.5% interferon ⁇ are used a ⁇ starting materials.
  • T-immunogenic peptides are constituted of rare sequence patterns. Use in the identification of T epitopes in the human immunodeficiency virus gag protein. Eur J Immunol 1988; 18: 1547-1553.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Methods and products for stimulating cell-mediated immunity against intracellular pathogens are provided. A foreign body is implanted into a subject to induce the formation of a fibrous capsule defining a chronic, local inflammatory site. An antigen associated with a pathogen then is presented at that site at a level appropriate for stimulating cell-mediated immunity. The antigen is presented by a solid, immunogenic, subcutaneous implant containing the antigen.

Description

IMPLANT STIMULATED CELLULAR IMMUNITY Field of the Invention This invention relates to methods and products for stimulating vivo cytotoxic T lymphocytes capable of killing cells infected with a pathogen.
Background of the Invention
Advances in medicine and public health have irradicated or significantly reduced the incidence of serious illness or death caused by many pathogens. Nevertheless, infectious diseases still are responsible for many serious health problems.
Technological advances in medicine, ironically, also have created some of the present, unsolved problems related to infectious disease. For example, immunosuppression resulting from medical treatments for cancer and transplants compromise the patient's defense system and create the opportunity for infection. Likewise, the use of antibiotics in hospitals has resulted in new strains of pathogens that are resistant to conventional antibiotic treatment.
One of the most serious health risks has resulted from a relatively new pathogen, the human immunodeficiency virus (HIV). This virus has had devastating effects, particularly in that it opens the door to infection by a variety of pathogens that previously were unimportant. Despite billions of dollars in research, an effective treatment for HIV infection has not been discovered to date.
The immune system is adapted among other things to protect mammals against infectious disease. It is comprised of cells derived from totipotent stem cells, and includes lymphocytes, monocytes/macrophages and granulocyteε. The lymphocytes are composed principally of two major groups: the thymus associated T cells and the antibody producing B cells. In birds, these antibody producing cells clearly originate in the burεa, thus, B cells. It is not at all clear that such a system exists in mammals. The term B cell, however, is utilized simply by convention. T cells represent the most complex subclasε in view of the range of specialized functions assumed by distinct subgroups. Certain T cells act to regulate T and B cell function by the production of cytokines and by contact. Other T cells can terminally differentiate into cytotoxic T lymphocytes (CTLs), which are responsible for cell-mediated immunity by lysing pathogen-infected cells.
CTLs are of two lineageε, characterized by the nature of the markers which they carry on their cell surface. These markers can be CD4 or CD8, the most predominant variety. The conditions required to cause a CD8 or CD4 cell to differentiate into a CTL are not well understood and are only now beginning to be elucidated. These conditions are complex and differ for CD8 and CD4 cells; for either cell type, various intercellular message molecules (cytokines) are involved. Cytokines play a major role in all forms of immunity and are at the heart of the inflammatory response. Since cytokines are so significant to the functional properties as well as specific differentiation of cell types —including whether or not a T cell expresses CD4 or CD8— the use of cytokines as a therapeutic modality has been attempted, unfortunately with only limited success.
Other cells of the immune system include those cells which are of the monocyte/macrophage lineage as well as granulocytes such as neutrophils. Macrophages arise from specific monocyte stimulation and represent one of the most versatile cells of the immune system, able to lyse and/or engulf foreign bodieε (bacteria, viruεes, etc.) and scavenge toxins and tumor cells. Macrophages respond to and are the source of numerous cytokines, including cytokineε that are responsible for T cell differentiation. Macrophages also present antigen to both CTLs and B cells in connection with stimulating cell-mediated immunity or inducing a humoral antibody response, respectively. One approach to the treatment of infectious disease is the use of vaccines. These are preparations that contain immunogens that are modified εo as to be incapable of producing the disease state, but capable of producing immunity against the pathogen. Vaccines have been very successful in treating some infections, but somewhat ineffective in treating otherε. This is perhaps due to the combination of the interaction between two complex systems, the host's immune system and the pathogen's system of replication.
For many years, various investigators have attempted to make improved vaccines for the purpose of enhancing the immune response or facilitating delivery of the vaccine. Some approaches have involved formulations adapted to provide sustained release of antigen. These approaches typically are adapted for stimulating a B cell response and are evaluated by measuring circulating antibody. They sometimes involve the introduction of agents which tend to suppress the local immune response to facilitate obtaining a desired level of circulating antigen. Presumably this is to ensure that antigen is delivered to regions of localized B cell differentiation. In one recent patent, U.S. patent no. 5,008,116, a different approach was taken; the implant was adapted to hold antigen at the site of the implant and to stimulate or suppress the immune response at that site. Antigens were physically entrapped in or chemically cross-linked to the interior of microporous microparticles. The micropores were of a size that would permit cellular infiltration. Agents for recruiting lymphocytes to the microparticles were suggested for inclusion in the microparticles.
One recent approach to treating a subject infected with the human immunodeficiency virus was to remove a sample of the subject's lymphocytes and stimulate them in vitro in the presence of an antigen associated with a specific pathogen. This produced a sub-sample of cells which was enriched for cytotoxic T lymphocyteε that recognized the antigen. The sub-sample of cytotoxic T lymphocytes was shown to be capable of lysing pathogen-infected cells of the subject. Accordingly, the sub-samples were administered to the subjects from which they were derived to treat the subject for the infectious disease.
It also was reported that CD8 T cells recognize antigenic peptideε preεented by MHC class I molecules and that for some infections, only a small number of peptides ( "immuno-dominant peptides") are capable of initiating the terminal differentiation of a CD8 cell into a cytotoxic T lymphocyte. If further was reported that cytotoxic T lymphocytes εpecific for εuch immuno-dominant peptideε are subject-specific and dominate the lytic response. Accordingly, when a subject's cytotoxic T lymphocyteε were removed for in vitro enrichment as deεcribed above, a panel of peptideε waε used to ensure that the appropriate antigen waε present for stimulating the subject-specific cytotoxic T lymphocyte response. In addition, it was suggested that such subject-specific peptides, once identified, could be administered intraveneously together with the sub-sample of cytotoxic T lymphocytes to further stimulate a cytotoxic T lymphocyte reεponεe in the infected εubject.
Summary of the Invention The invention provideε methodε and products for stimulating in vivo cell-mediated immunity against pathogen-infected cells. It involves forming a local, chronic, inflammatory site and presenting an antigen associated with a pathogen at that εite at a level appropriate for εtimulating cell-mediated immunity against cells infected with the pathogen. Conditionε are created at the local inflammatory site which favor the terminal di ferentiation of T cells into cytotoxic T lymphocytes. T cellε thus are continually recruited and expanded, thereby maximizing the potential for a vigorous cytotoxic response against the pathogen infected cells.
According to one aspect of the invention, novel sustained-released devices are provided. The devices are solid, immunogenic implants that induce, when implanted subcutaneously, the formation of a subcutaneous fibrous capsule defining a chronic inflammatory site. The implant contains an antigen associated with a pathogen. The implant iε conεtructed and arranged to preεent the antigen for an extended period of time at a level appropriate for stimulating cell-mediated immunity, but at a level that does not induce tolerance.
The implant can be free of materials that suppress the immune response.
It is preferred that the implant contain a cytokine or a combination of cytokines for stimulating cell-mediated immunity. Most preferably the implant includes the cytokines interleukin 2, interleukin 4, interleukin 8, interleukin 12 and interferon γ, and it is preferred that the implant be constructed and arranged to deliver the cytokine for the same period of time that the antigen is being presented. The implant also can contain an agent for εuppreεsing the conversion of macrophages into foam cells, and preferably the agent iε an antioxidant.
According to another aspect of the invention, a subcutaneous fibrous capsule defining a chronic, local, inflammatory site is created in the εubject by implanting εubcutaneously a foreign body. An antigen associated with the pathogen then is presented continuously at a level appropriate for stimulating cell-mediated immunity, but at a level that does not induce tolerance. The antigen can be delivered using the devices described above.
The invention is particularly useful in the treatment of a subject infected with HIV. The chronic presentation of low doεes of antigen in the environment of the fibrous capsule can produce a cytotoxic T cell response directed to HIV infected cells. Such a cytotoxic T cell reεponεe iε believed to be crucial in combating HIV infection and in preventing or arresting the development of Autoimmune Deficiency Syndrome (AIDS) .
These and other aεpectε of the invention are described in greater detail below.
Detailed Description of the Invention The invention involves forming a discrete, localized site of chronic inflammation, and using this site of inflammation as a local 'factory' for the production of cytotoxic T lymphocytes (CTLs) that will lyse cells infected with a specific pathogen. The expanded set of CTLs specific for a pathogen can erradicate or prevent the development of infection and alεo can be used to treat or arrest the development of cancers associated with infection.
When a solid, appropriately immunogenic, foreign body iε introduced subcutaneouεly into a subject, a complex cellular response takes place which can result in the implanted object being encapsulated by a dense, fibrous capsule or compartment. The capεule is often characterized by new capillarieε of both blood vesεels and lymphatics. It is believed that this process begins with the chemotaxis of neutrophils and monocyte/macrophages to the site of "injury", probably enlisted by the presence of platelet derived growth factor (PDGF) and granulocyte/macrophage colony stimulating factor (GM-CSF) . Macrophages apparently coat the object while simulataneouεly stimulating fibroblasts to begin constructing the fibrouε "wall".
The capsule iε highly structured, consiεting of an inner lumen which can be lined with a layer of looεe cellular material, a middle fibrous layer, and an outer loose connective tissue layer. The middle layer contains we11-developed blood vesεelε and lymphatics and can be on the order, for example, of one half to thirty millimeters in thickness (thousandε of cells in thickness). The cellular compartment contains numerous round cells, macrophages and fibroblasts. The macrophageε eεεentially coat the foreign body.
To achieve the complexity of the capεule and the apparent continuouε cellular turnover, εignificant cytokine involvement is necessary, and it is believed that the lumen of the capsule is rich in cytokines.
Thus, a naturally-occurring, local inflammatory microenvironment is generated. The term "local inflammatory microenvironment" pertains to chronic, nonpathogenic, tissue responses characterized by: (1) macrophage stimulation and chemotaxis; (2) fibroblast stimulation and collagen deposition to form a dense fibrous capsule; and (3) development and infiltration of neovasculature (angiogenesis) and lymphatics. Not all foreign body responεes and granulomas are the same as they relate to the relative preεence of these components.
While the inventor does not wiεh to be bound by any theory of the invention, it iε believed that chemotaxis attracts lymphocytes and macrophages to the site of inflammation within the vascularized fibrous capsule. Since the implant appears to remain coated with macrophages throughout, it is believed that the environment is particularly εuited for antigen preεentation to circulating lymphocytes and the creation of cytotoxic T lymphocytes.
It is unclear whether B cell stimulation is enhanced significantly. It may be that in certain circumεtances, the B cell response is actually suppressed. If desired, the B cell responεe can be suppressed by including B cell suppressing agents in the implant.
As discussed above, the specific regulation of this inflammatory microenvironment appears to be modulated by naturally occurring, locally acting, cellular regulatorε, which affect colony εtimulation, angiogenesis and tissue generation within the microenvironment. See, e.g., K. Arai et al. , "Cytokines: Coordinatorε of Immune and Inflammatory Reεponses", Annu. Rev. Biochem. , 59:783-836 (1990). As discuεεed in parent application serial no. 07/699,763, this local microenvironment also can be manipulated by including cellular regulatorε in the implant. Such cellular regulatorε previouεly were uεed to affect the development of the fibrouε capsule and its vasculature, thereby affecting the release-kinetics of drugs contained in the implant.
The present invention is designed to exploit this same local, inflammatory microenvironment for the purpose of generating a cell-mediated immune response to a pathogen-εpecific antigen. This local inflammatory microenvironment is particularly suited for recruiting the components of the cell-mediated immune system (e.g. macrophages, T-lymphocytes) and for creating an environment well-suited for the processing and presentation of antigens and the proliferation of CTLs.
The invention involves presenting an antigen associated with a pathogen within this microenvironment at a frequency or "dose" that is appropriate for stimulating cell-mediated immunity, but is low enough such that tolerance is not induced. As will be described in greater detail below, agents for inducing a vigorous CTL response may be introduced into this microenvironment (in addition to such agents as occur naturally within the local microenvironment).
The invention is useful in connection with stimulating cell-mediated immunity in mammals infected with an intraceUular pathogen such as a virus, bacterium, fungus or protozoan. "IntraceUular pathogen" means a disease-causing organism which resideε, during at least part of its life cycle, within a host cell.
Viruses include but are not limited to those in the following families: picornaviridae; caliciviridae; togaviridae; flaviviridae; coronaviridae; rhabdoviridae; filoviridae; paramyxoviridae; orthomyxoviridae; bunyaviridae; arenaviridae; reoviridae; retroviridae; hepadnaviridae; parvoviridae; papovaviridae; adenoviridae; herpesviridae; and poxyviridae.
Bacteria include but are not limited to: P. aeruginosa; E. coli; klebεiella; serratia; pseudomonas; B. fragiliε; P. cepacia; acinetobacter; N. gonorrhoeae; S. epider iε; E. faecalis; S. pneumoniae; S. aureus; haemophilus; neisseria; N. meningitidis; bacteroides; citrobacter; branhamella; salmonella; shigella; S. pyogeneε; proteuε; clostridium; erysipelothrix; leεteria; L. monocytogeneε; paεteurella multocida; streptobacillus; spirillum; fusospirochetes; treponema pallidum; borrelia; actino ycetes; mycoplasma; chlamydia; rickettsia; spirochaeta; legionella pneumophila; mycobacteria; ureaplasma; strepto yces; C. difficite; trichomoras; and P. mirabilis.
Fungi include but are not limited to: cryptococcus neoformans; blastomyces dermatitidis; ajellomyceε dermatitidiε; histoplasma capsulatum; coccidioideε immitiε; Candida, including C. albicanε, C. tropicalis, C. parapsiloεis, C. guilliermondii and C. krusei; aspergilluε, including A. fumigatus, A. flavuε and A. niger; rhizopus; rhizomucor; cunninghammella; apophysomyceε, sakεenaea, mucor and absidia; sporothrix schenckii; P. brasiliensis; pseudallescheria boydii; T. glabrata; and dermatophytes.
Treatment or prevention of infection by the following pathogens is preferred:
Human immunodeficiency virus (including, without limitation, HIV-l and HIV-2); human T cell leukemia virus (including, without limitation, HTLV-I and HTLV-II); herpes virus (including, without limitation, Herpes simplex type 1 and type 2, Herpes zoster, and cytomegalovirus as well as epstein-barr viruε; papillomavirus; hepatisis (including, without limitation hepatiεiε A, B and C); creutzfeldt-Jacob viruε; feline leukemia viruε; micobacteria (including, without limitation, M. tuberculoεis and M. leprae); pneumosystis carinii; cryptococcus neoformans; Candida (including, without limitation, Candida albicans and Candida tropicalis); mycoplasma; toxoplasma gondii, qiardia lamblia; trypanoso a cruzi; organisms of the genus leiεhmani; and organisms of the genus plasmodium.
The invention is particularly useful when a T cell responεe iε important in treating or preventing an infection by a pathogen. Most preferred is treatment or prevention of infection by human immunodeficiency virus.
The antigen selected for use in connection with the present invention will depend upon the particular diseaεe being treated. It may be any antigen aεsociated with the pathogen. The antigen can be a plurality of antigens or a single, defined epitope. It can be whole and/or attenuated viruε, bacterium, funguε or protozoan. It can be any portion thereof, isolated according to procedures well known to those of ordinary skill in the art. For example, it can be a component of a pathogen isolated by disrupting the pathogen and isolating the component. It alεo can be produced by mutation and/or recombinantly aε a mutant pathogen. It can be whole protein, fuεion protein, peptide, or part of a vector εuch as part of a vaccinia vector. It further can be produced synthetically, such aε a peptide εyntheεized de novo, or it can be derived from a related organiεm (e.g. Bacillus Calmette-Guerin (BCG) in the case of tuberculosis) . The invention in its broadest aspect is not intended to be limited by the selection of the particular antigen or by its mode of preparation. Those of ordinary skill in the art will have available to them well characterized antigens previously used, for example, as vaccines for treating the various conditions diεcussed herein. Thuε, aε used herein, an "antigen associated with a pathogen" is any antigen that is capable of inducing a cell-mediated immune response and capable of being recognized by a cytotoxic T cell aε part of the pathogen or a cell infected with the pathogen. In the case of human immunodeficiency virus, many antigenic components have been well characterized and cloned. Some antigenic components include nuclear materials which are expresεed on the εurface of cells infected by the human immunodeficiency virus. Other antigenic components include peptides. The following iε a list of epitopes reported to be capable of εtimulating CTLε .
TABLE I
CTL EPITOPES
•CLASS I RESTRICTED
Protein Amino Residues HLA Type Reference
Acidε nef
66-80 VGEPVTOVPLRPMT Al 1
73-82 QVPLRPMTYK A3.1 2
73-82 QVPLRPMTYK A3,A11,B35 3
83-94 AAVDLSHFLKEK All 3
93-106 EKGGEGLIHSQRR Al 1
113-128 WIYHTOGYFPDWQNYT Al 1
115-125 YHTQGYFPDWQ B17 3, 4
117-128 TQGYFPDWQNYT B17,B37 3
126-138 NYTPGPGVRYPLT B7 3
132-147 GVRYPLTFGWCYKLVP B18 3
132-147 GVRYPLTFGWCYKLVP Al 1
182-198 EWRFDSRLAFHHVAREL Al 1
192-206 HHVARELHPEYFKNC Al 1 pol
172-196 IETVPVKLKPGMDGPKVKQWPLTEE B8 5
205-219 CTEMEKEGKISKIGP ?
6
325-349 AIFQSSMTKTLEPFRKQNPDIVIYQ All 5
342-366 NPDIVIYQYMDDLYVGSDLEIGQHR All 5
359-383 DLEIGQHRTDIEELRQHLLRWGLTT Bw60 5
461-485 PLTEEAELELAENREILKEPVHGVY A2 5
495-519 EIQKQGQGQWTYQIYQEPFKNLKTG All 5 qaq pl7 (MA) 18-42 KIRLRPGGKKKYKLKHIVWASRELE Bw62 7
21-35 LRPGGKKKYKLKHIV B8 8
69-93 QTGSEELRSLYNTVATLYCVHQRIE A2 7
71-85 GSEELRSLYNTVATL A2 8
86-115 YCVHQRIEIKEEQNKSKKKA A2 9 p24 (CA) 143-164 VHQAISPRTLNAWVKWΞEKAF Bw57 7
143-157 VHQ ISPRTLNAWVK ? 8
153-174 NAWVKWEEKAFSPEVIPMFSA Bw57 7
185-199 DLNTMLNTVGGHQAA B14 8 193-203 GHQAAMQMLKE A2 10 219-233 HAGPIAPGQMREPRG A2 10 253-267 NPPIPVGEIYKRWII B8 11 253-274 NPPIPVGEIYKRWIILGLNKIV B8 7 262-284 YKRWIILGLNKIVRMYSPTSILD Bw62 7 263-277 KR IILGLNKIVRMY B27 12 293-307 FRDYVDRFYKTLRAE ? 8 303-314 TLRAEQASQEVK B14 13 305-313 RAEQASQEV B14 7 323-337 VQNANPDCKYILKAL B8 8 342-357 LEEMMTACQGVGGPG ? 8 353-363 VGGPGHKARVL ? 8 p7 (NC) 418-433 KEGHOMKDCTERQANF A2 10 446-460 GNFLQSRPEPTAPPF A2 10 env gpl20 34-55 LWVTVYYGVPVWKEATTTLFCA A2 14
105-117 HEDIISLWDQSLK A2 15
188-207 TTSYTLTSCNTSVITQACPK A2 14
219-307 SVEINCTRPNNNTRKSI A2 14
308-322 RIQRGPGRAFVTIGK (mouse) Dd 16
308-322 RIQRGPGRAFVTIGK A2 15
369-375 PEIVTHS A2 14
379-390 GGEFFYCNSTQL A2 17
416-435 LPCRIKQFINMWQEVGKAMY A2 14
421-439 KQIINMWQKVGKAMYAPPI A2 15
489-508 VKIEPLGVAPTKAKRRWQR A2 14 gp41 584-592 ERYLKDQQL B14 13
586-593 YLKDQQLL B8 13
770-780 RLRDLLLIVTR A3.1 18
827-841 DRVIEWQGACRAIR A2 15
CLASS II RESTRICTED env gpl20 309-316 IQRGPGRA not identified 19
310-316 QRGPGRA(FVTI) 19 312-318 GPGRAFV(TI) 19 410-429 GSDTITLPCRIKQFINMWQE DR4 20 gp41 579-590 RILVERYLKDQ DPw4.2 21
It is to be noted that peptides may be subject specific. The subject then may need to be tested in advance of treatment according to the present invention to determine the identity of peptides most uεeful for stimulating cellular immunity. Such a procedure has been developed for subjectε infected with human immunodeficiency virus, and is reported in PCT application PCT/US91/06441 , publication no. WO92/04462, published March 19, 1992. For influenza, a peptide fragment of influenza matrix protein shown to be restricted by HLA-A2 may be used: TKGILGFUFTLTV. This peptide, presented by self-MHC, has been shown to induce an increase in CTL proliferation Jj vitro in the presence of a combination of interleukin-12 and low-dose interleukin-2 (εee M. Bertagnolli, B-Y Lin, D. Young and S. Herrmann, IL-12 Augmentε Antigen-Dependent Proliferation of Activated T-lymphocytes, J. Immun. , V. 149, 3778-3783, No. 12, 12/15/92).
Reference also may be made to Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Co., Easton, PA 18042 (1990) for details with respect to the preparation of and commercial sources for various antigens and vaccines.
Cytokines may be delivered to the microenvironment and used to induce CTL proliferation. Theεe introduced cytokineε will augment the stimulatory effect of the cytokineε occurring naturally in the microenvironment of the fibrouε capεule. Cytokines are factors that εupport the growth and maturation of cellε, including lymphocytes. Important to the invention herein is activating those cells reεponsible for cell-mediated immunity and the generation of CTLs. Cytokines are known to participate in such activation.
The following is a list of cytokines known to the inventor.
TABLE II
CYTOKINE SOURCE FUNCTION
Interleukins
IL-1 Macrophage Proliferation of activated
T-cells; induction of macrophages to make cytokines
IL-2 T-cell Activates killer cells
IL-3 T-cell Growth, hematopoiesiε
IL-4 T-cell Growth, activation of T cells IL-6 Macrophages Growth of eoεinophilε IL-7 Stromal cells Growth of T cells
IL-8 Monocytes Chemotaxis of T cells IL-9
IL-10
IL-11
IL-12 Activates T cells
Colony Stimulating Factors
GM-CSF T-cell,macrop
Macrophage growth G-CSF Fibroblaεts Growth of granulocytes
M-CSF Fibroblastε Growth of macrophage colonies
Tumor Necrosis
Factors
TNF-alpha Macrophageε Tumor cytotoxicity TNF-beta T-cells Activates cytokine production
Interferons
IFN-gamma T-cells Activates macrophages Growth Factors
Platelet-derived growth factor Platelets Epidermanal growth factors Transforming growth factor Macrophages Fibroblast growth factor
To promote the production of CTLε specific for antigen, use of the following combination of cytokines is preferred: IL-2, IL-4 and IL-12 for activating T cells; IL-8 for chemotactic recruitment of T cells; and interferon γ for activating macrophages.
The precise amounts of the foregoing compounds used in the implants of the invention will depend upon a variety of factors, including the nature of the antigen and the duration that the implant is to laεt. It will be underεtood, however, that daily preεentation of very εmall amountε (picogramε) are required because only local presentation within the fibrous capsule are necesεary to achieve the purpoεes of the invention.
The preciεe amountε can be determined without undue experimentation. The threεhold amountε of cytokineε to achieve a particular reεult have been tested in the art both in vivo and _in vitro. The maximum amounts may be determined for achieving the higheεt levelε of antigen-specific CTLs by formulating implants and teεting for the preεence of CTLs. It will be understood, however, that practically any amount, no matter how small, of the preferred cytokines should be useful in promoting the differentiation of precursor T cells into CTLs. It further will be understood that the art teaches that low doseε of IL-2 with IL-12 are particularly useful in stimulating the production of CTLs (see M. Bertagnolli, id). It is believed that cytokines present in the following ranges will be quite suitable for achieving the purposes of the invention.
IL-2 10 picograms to 10 nanograms presented daily.
IL-12 10 picogramε to 10 nanogramε preεented daily.
IFN γ 10 picogramε to 10 nanogramε preεented daily.
The antigenε are presented subcutaneously as solid aggregateε. A "εolid aggregate" aε used herein means an article of the type that can continue to present at its surface, over an extended period of time, an agent when implanted in vivo. Such devices can be constructed entirely of the agent itself, such as a totally melted and recrystallized pellet of antigen. They alεo can be conεtructed of the agent together with a bioerodible excipient εuch aε choleεterol . They further can be contained in a nonerodible matrix εuch aε a εilastic matrix. Important for the purposeε herein is that the device is capable of preεenting the agents, i.e. antigens, at levels that are appropriate for stimulating cell-mediated immunity but at a dose that typically does not induce tolerance. The solid aggregate devices useful herein thus can present continuously very εmall amounts of antigen for periods from two months to two years or more. The level of antigen present at the surface of the solid aggregate and taken up by the macrophages per day preferably is less than fifty micrograms per day, in order to prevent tolerance and most preferably is in the nanogram or even picorgram range. Extremely low levelε of presentation are posεible becauεe the converεion of T cellε into CTLs occurs in the local microenvironment of the fibrous capsule.
Because the implant is coated entirely with macrophages in the lumen of the capsule, antigen is said to be presented, not released. Free antigen in the blood stream may not even be detectable, since macrophages preferably are binding all antigen within the capεule. Thus, the capsule is intended to create an environment rich in cells, cytokines and antigen for stimulating within the capsule the desired immune responεe. Thiε differε from the prior art which doeε not teach implants containing antigen that form such capεuleε and which seek principally to produce a humoral response, and/or action at a distance.
It will be understood that IL-2 tends to prevent the induction of anergy in T cells. Likewise, CD28 stimulation by CD28 agonists including by anti-CD28 antibodies or fragments thereof tend to prevent the induction of anergy. Thus, higher doses of antigen may be presented in the presence of such substances without resulting in tolerance.
In preparing the implant, it iε desirable to take into account the type of antigen being employed. It is believed that all cells expreεεing CD8 have the potential of developing into CTLε . Some, but not all, cellε expressing CD4 have the same potential. CD8 cells have been reported to respond to peptides, not proteins. Therefore, if the antigen is only whole protein, it is posεible that only CD4 cellε will be stimulated. On the other hand, it has been reported that CD8 cells will respond only to particular subject-specific, immunodominant peptides (See PCT publication no. WO92/04462), and therefore it may be desirable to prescreen a subject to identify those peptides to which the subject will respond maximally if using only peptideε as an antigen. Nevertheless, the environment of the fibrous capsule may be εuch as to degrade protein, and CD8 cells still may be activated even when whole protein iε delivered via the implant. It also will be understood by those of ordinary skill in the art that CD8 cells and CD4 cells respond to different cytokines and signals. Therefore, the antigen selected may also determine the accessory molecules presented with the antigen, such aε cytokines or other signalling molecules.
As discussed above, INF γ may be included in the implant to activate macrophages for presenting antigen. Other materials also may be added to enhance the environment relative to macrophage or T cell activation. For example, oxidated LDL can stimulate macrophages to become foam cells. As discussed herein, the fibrous capsule defineε a chamber that containε the implant. Surrounding the implant and within the chamber are a variety of cells, including both macrophages and foam cellε. Macrophages are the precursors of foam cells and are activated to become foam cells by a variety of mechanisms. The most common mechaniεm iε the interaction of a receptor on the macrophage with oxidated low-density lipoprotein (oxLDL) . The oxLDL is produced by oxidizing low-density lipoprotein, and it has been reported that such oxidation is asεociated with εiteε of chronic inflammation. In some inεtances, it may be desirable to prevent such activation to maintain the macrophageε in a state that is optimal for antigen preεentation to T cells. IL-2 is believed to be one such agent. Activation also can be reduced by preventing the formation of oxLDL in the environment of the fibrous capsule. This can be achieved by continuously releasing an anti-oxidant into the environment of the inflammatory site. Anti-oxidantε include vitamin E, butylated hydroxytoluene, etc. Aε will be underεtood by those of ordinary skill in the art, virtually any molecule that participates in the conversion of a T cell to a CTL may be preεented at the εite of inflammation in accordance with this invention. Many such molecules are known to those of skill in the art, including, without limitation, anti-CD3 antibody and in particular solid phase anti-CD3 antibody, phorbol esters, aloe antigen, B7 and the like. The implants of the invention also may include adjuvants for enhancing the CTL reεponse.
The implants of the invention may be used prophylactically or therapeutically. When used prophylactically, they typically are given to a subject that is at risk of being infected by a pathogen. When used therapeutically, they typically are given to a subject that is known to have or that is suεpected of having developed an infection by a pathogen. Aε used herein, a subject means a human, primate, horse, cow, sheep, goat, pig, dog, cat or rodent. The preferred sustained release devices are solid, immunogenic, subcutaneous implants that induce the formation of a fibrous capsule defining a chronic inflammatory site. By "solid" implant it is meant solid enough to permit the formation of a dense fibrous capsule εurrounding the implant prior to substantial dissipation or degradation of the implant.
Suitable implants for use in connection with the invention are compressed pellets wherein an antigen, alone or together with an excipient, is compresεed under high preεεure into a solid implant. A preferred implant is a nonpolymeric εyεtem comprising a fused pellet. In a fused pellet, an antigen, a carrier, or both are melted and recrystallized to form a crystaline matrix of the antigen and/or nonpolymeric carrier. In a totally fused pellet, both the antigen and carrier are melted and recrystallized. In a partially fused pellet, only the carrier is melted and recrystallized, thereby capturing the antigen in the crystaline matrix of the carrier. A partially fused pellet is particularly suitable for the delivery of proteins or peptides whose conformation and properties might be compromised if heated to their melting temperature. Thus, a carrier having a lower melting temperature than the peptide or protein is heated to the melting point of the carrier, and then recrystallized to form a matrix encapsulating the peptide or protein. Stearols are particularly suited for melting and recrystallization. For example, various cholesterol-type compounds including cholesterol acetate may be used. Compounds such as palmitic acid also may be used. The particular methods for forming fused pellets are disclosed in U.S. patent nos. 4,748,024, 4,892,734 and 5,039,660 (all to Leonard), the entire disclosureε of which are incorporated herein by reference.
Another preferred embodiment iε the use of a jacketed implant which iε the subject of co-pending application serial no. 07/565,273, "Multiple Drug Delivery System", the disclosure of which is incorporated herein by reference. In this embodiment, cellular regulators are combined in a matrix with a bioerodible polymer, such as poly-DL lactide or glycolyde, as a sheath around a core implant including the antigen. The sheath is formed so as to gradually erode, releasing the cellular regulator and preparing the tissue environment for presentation of the antigen contained in the core. These regulators would be released early and for the time period of formation of the fibrous capsule. Whether or not the sheath contains a cellular regulator, the sheath or a complete coating can be used to delay the presentation of antigen until a dense fibrous capsule has been formed.
The antigen also may be presented in polymeric εyεtems. A polymeric system consistε of matriceε of polymerε combined with the antigen. Such systemε include systemε in which the antigen is distributed in or covalently attached to a biodegradable polymer matrix. Biodegradable polymers that have been used in such systemε include hydroxycarboxylic acids, especially lactic acid and glycolic acid. Cholesterol and ethylene vinyl acetate copolymers have alεo been uεed. See, for example, U.S. Patent No. 4,591,496 iεεued to Cohen et al . , which describes a polymeric system consiεting of mixing a drug and a polymer, e.g. ethylene-vinyl acetate copolymer powderε, below the glaεε tranεition temperature of the polymer, and compressing the mixture at a temperature above the transition point.
Bioerodible polymers include hydroxycarboxylic acids, especially lactic acid and glycolic acid, polycaprolactone and copolymers thereof. For inεtance, variouε proportionε of lactide and glycolyde can be employed, εuch as 50/50, 65/35, 75/25, and 85/15 percent weight ratios of poly (DL-lactide-co-glycolide) . In addition, substantially 100% weight percent poly (DL-lactide) , poly (L-lactide), and polyglycolide can be used. Bioerodible polymers of this type are obtained from Birmingham Polymers, Inc., Birmingham, Alabama 35222. Copolymers of gluconic acid and ethyl-L-glutamic acid and other polypeptideε can be uεed, as well as poly(orthoeεters) (Choi et a]. . , U.S. Patent No. 4,093,709) and poly(orthocarbonate) (Schmitt, U.S. Patent No. 4,346,709). Also, poly(acrylate) materials can be employed, such as copolymers of acrylic and methacrylic acid esters or copolymers of methacrylic acid and methyl methacrylate (Sothmann et al . , U.S. Patent No. 4,351,825). Cholesterol and ethylene vinyl acetate copolymers can also be used. See for example, U.S. Patents 4,452,775 (J.S. Kent) and 4,591,496 (J.M. Cohen et al..), respectively.
If a polymeric matrix is employed, it must be fashioned to be a "solid aggregate" as defined herein. The matrices of the prior art typically were used for releasing circulating amounts of antigen for inducing a B-cell responεe. They alεo typically were porouε, permitting tiεεue infiltration and/or were erodible or nonimmunogenic to an extent where a denεe fibrouε capεule did not form. Knowing as a result of this invention that a dense fibrous capsule can form as a result of implanting a solid, immunogenic foreign body and that εuch a capεule is desirable for presenting antigen, those of ordinary εkill in that art will be able to manufacture solid, immunogenic implants from polymer matrices.
Other implants are made of inert materials. The term "inert" refers to implants that are not eroded or otherwise structurally compromised when implanted. Exemplary materials include polytetrafluoroethylene (Teflon®), plastic, silicone or ceramic materials.
The invention also provides methods and productε for treating cancer. Certain viruses are associated with cancer and are expressed on -neoplastic cells, but not normal cells. These include hepatisis B, Epstein Barr virus and human pampalloma virus. The methods and products of the invention thus are adapted for stimulating cell-mediated immunity against viral cancer antigens for the purpoεe of producing cytotoxic T cellε againεt neoplaεtic cells. These viral antigens are known to those of ordinary skill in the art. The best characterized cancers include melanomas, ovarian cancers and renal cancers.
Example I
A solid implant for stimulating cell-mediated immunity against influenza virus.
The peptide fragment of influenza matrix protein, described above, is homogeneously distributed and captured in a matrix of a melted and recrystallized nonpolymer carrier. The carrier, powdered cholesterol acetate obtained from Sigma Chemical Co. of St. Louis, MO., has a lower melting point than the influenza peptide and is εelected εo that when a homogeneouε mixture of the choleεterol acetate and peptide iε heated, a partial melt may be formed with substantially all of the carrier melting and substantially all of the peptide not melting. The partial melt then is allowed to cool, with the cholesterol acetate recrystallizing to form the hardened pellet and capture the influenza peptide. Pelletε of the foregoing type are formed aε described in U.S. patent 5,039,660, the entire disclosure of which is incorporated herein by reference. Briefly, fluorocarbon tubeε that are εtraight cylinderε having an inner diameter of 0.095 inches, an outer diameter of 0.135 inches and a length of 0.625 incheε are provided. Such tubing iε εold under the name of Teflon-TFE, Norton Chemplaεt, Inc., of Wayne, N.J. Next, the powdered choleεterol acetate and the influenza peptide are combined in approximate proportionε of 10% peptide and 90% cholesterol acetate (weight/weight) . The mixture is dispensed into the fluorocarbon tube in an amount such that when dried, the remaining powder equals 2ml in depth after a first compression phase. Approximately 20g of powder in the form of a paste is added to the tube using a pipette. A vacuum force then is applied acrosε the filter εheet to evaporate the solvent.
Accurate dispenεing of the εtarting materials can be achieved by forming the paste which is made from a powdered mixture of the starting materialε and a liquid εuch as ethyl alcohol. The alcohol may be dried out of the starting materials after dispensing, utilizing, for example, a standard vacuum oven. By forming a paεte, the material can be dispensed accurately from a standard, automated device such as a micropipeter. The paεte may be manufactured to have the flow characteristics of ordinary toothpaste. For further details, see U.S. patent 4,892,734, issued 1/9/90 to Leonard, the entire disclosure of which is incorporated herein by reference.
The tube is plugged with a 3mm piece of Teflon beading, and the dry mixture then is compressed against the plug, using a steel pin inserted into the end of the tube opposite the plug. The plug end is held against a solid surface to prevent the plug from being expelled from the tube. The degree of compression corresponds to about 2200 p.s.i. for three seconds. The tube containing the compressed dry mixture then is transferred on the pin to an oven preheated to 180°F. The tube is exposed to this environment for 30 seconds. The tube then is removed from the oven and is compressed by hand at about 150 p.s.i. for about six secondε aε the partially-melted material cools and recrystallizeε to form a hardened pellet. The mixture iε allowed to cool for an additional three minuteε without any compreεεion and, finally, the plugs and pellets are ejected from the tubes. The pellets then may be used for subcutaneous implantation. Pellets of the foregoing type are commercially available from Endocon, Inc., Walpole, MA, U.S.A.
One method of administering the implant is using an injector of the type described in U.S. patent 4,846,793, the entire disclosure of which is incorporated herein by reference. Such injectors also are sold by Endocon, Inc.
The formed pellet is implanted subcutaneously in a mammal and a fibrous capsule surrounding the implant is permitted to form. Each week, a sample of peripheral blood iε collected and teεted for the preεence of cytotoxic T cells active against cellε infected with influenza virus. Procedures for collecting blood and testing for the presence for influenza-specific cytotoxic T cells are well known to those of ordinary skill in the art.
Example II
A solid implant for stimulating cell-mediated immunity against influenza viruε, the implant containing cytokines.
Same aε Example I, except that the mixture includeε 10% influenza matrix peptide, 88% choleεterol acetate, 0.8% Interleukin-12, 0.4% Interleukin-2, 0.4% Interleukin-8, 0.2% Interleukin-2 and 0.2% Interferon γ.
Example III
A εolid implant for εtimulating cell-mediated immunity againεt human immunodeficiency viruε.
The procedure of Example I is followed, except that 90% cholesterol acetate and 10% of an HIV-CTL epitope are used as starting materials. Example IV
A solid implant fcr stimulating cell-mediated immunity against human immunodeficiency viruε, the implant containing subject-specific immunodominant peptides.
The same as Example I, except that 95% cholesterol acetate and 5% of a subject-specific immunodominant peptide are used as starting materials. The subject-specific immunodominant peptide is identified as deεcribed in U.S. patent application serial no. 07/578,828, filed September 6, 1990, the entire disclosure of which is incorporated herein by reference.
Example V
The same as Example I, except that 80% cholesterol acetate, 15% influenza peptide, 4% Interleukin-12 and 1% Interleukin-2 are used as starting materialε.
Example VI
The same as Example I, except that 96% cholesterol acetate, 2% influenza peptide, 1% Interleukin-12, 0.5% Interleukin-2 and 0.5% interferon γ are used aε starting materials.
EQUIVALENTS
Thoεe εkilled in the art will be able to aεcertain, using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein,
These and all other equivalents are intended to be encompasεed by the following claims.
REFERENCES
(1) B. Autran, et al, as reported in reference 8.
(2) Koenig S. Fuerst TR, Wood LV, Woods RM, Suzich JA, Jomes GM, de la Cruz VF, Davey RT, Jr, Venkatesan S, Moss B. Biddison WE, and Fauci AS: Mapping the fine specificity of a cytolytic T cell response to HIV-l nef protein. J. Immunol 1990; 145: 127-135. (3) Culman B, Comard E, Kieny M-P, Guy B. Dreyfus F Saimot A-G, Sereni D, and Levy J-P: Six epitopes reacint with human cytoxic CD8+ T cells in the central region of the HIV-1 nef protein. J Immunol 1991; 146: 1560-1565.
(4) Culir.ann B, Comard E, Kieny M-P, Guy B. Dreyfus F Saimot A-G, Sereni D, and Levy J-P: An antigen peptide of the HIV-l nef protein recognized by cytotoxic T lymphocytes of seropoεitive individualε in aεεociation with different HLA-B moleculeε. Eur J Immunol 1989; 19: 2883-2386.
(5) Walker BD, Flexner C. Birch-Limberger K, Fiεher L. Paradiε TJ, Aldovini A, Young R, Moss B, and Schooley RT: Long-term culture and fine specificity of human cytotoxic T-lymphocyte clones reactive with human immunodeficiency viruε type 1. Proc Natl Acad Sci (USA) 1989; 86: 9514-9518.
(6) Hosmelin A, Clerici M. Houghten R, Pendleton CD, Flexner C. Lucey DR, Moss B. Germain RN, Shearer GM, and Berrofsky JA. An epitope in human immunodeficiency virus 1 reverse transcriptaεe recognized by both mouse and human cytoxic T lymphocytes. Proc Natl Acad Sci (USA) 1990; 87: 2344-2348.
(7) Johnson RP, Trocha A, Yang L, Mazzara GP, Panicali DL, Buchanan TM, and Walker BD: HIV-l gag-εpecific CTL recognize multiple highly conεerved epitopeε: Fine εpecificity of the gag-εpecific reεponεe defined uεing unεtimulated PBMC and cloned effector cellε. J Immunol 1991; 147: 1512-1521.
(8) Nixon D, and McMichael AJ: Cytotoxic T-cell recognition of HIV proteins and peptides. AIDS 1991; 5: 1049-1059. (9) Achour A, Picard 0, Zagury D, Sarin PS, Gallo RC, Naylor PH, and Goldstein AL: HGP-30, a synthetic analogue of human immunodeficiency viruε (HIV) pl7, iε a target for cytotoxic lymphocyteε in HIV-infected individualε . Proc Natl Acad Sci (USA) 1990: 87: 7045-7049.
(10) Claverie J-M, Kourilsky P, Langlade-Demoyen P, Chalufour-Prochnicks A, Dadaglio G, Tekaia F, Plata F, and Bougueleret K: T-immunogenic peptides are constituted of rare sequence patterns. Use in the identification of T epitopes in the human immunodeficiency virus gag protein. Eur J Immunol 1988; 18: 1547-1553.
(11) Gotch FM, Nixon DF, Alp N, McMichael AJ, and Boysiewicz LK: High frequency of memory and effector gag specific cytotoxic T lymphocytes in HIV seropoεitive individualε. Internat Immunol 1990; 2: 707-712.
(12) Nixon DF, Townsend ARM, Elvin JG, Rizza CR, Gallway J. and McMichael AJ: HIV-l gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 1988; 336: 484-487.
(13) Johnson RP, Troch A, Earl P, Mosε B, Buchanan TM, and Walker BD: Identification of a conεerved CTL epitope in the HIV-l gp4l envelope recognized by B8- and Bl4-reεtricted T-lymphocyte cloneε. VII International conference on AIDS. Florence, June 1991 [abstract WA.1206].
(14) G. Dadaglio, et al, as reported in reference 8.
(15) Clerci M, Lucey DR, Zajac RA, Boswell RN, Gabel HM, Takasahi H, Berzofεky JA, and Shearer GM. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gpl60 in HIV-εeropositive individuals, J. Immunol 1991; 146: 2214-2219. (16) Takahaεhi H, Cohen J, HOsmalin A, Ceaεe KB, Houghten R, Cornette JL, DeLiεi C, Mosε B, Germain RN, and Berzofεky JA: An immunodominant epitope of the human immunodeficiency viruε envelope glycoprotein gpl60 recognized by class I major histocompatibility complex moleculte-reεtricted murine cytotoxic T lymphocytes. Proc Natl Acad Si (USA) 1988; 85: 3105-3109.
(17) Walker BD, and Plata F: Cytotoxic T lymphocytes against HIV. AIDS 1990; 4: 177-184.
(18) Takahashi K, Dai L, Fuerst TR, Biddison WE, Earl P, MOsε B, and Enniε FA: Definition of a conserved HLA-A3, restricted CTL epitope on HIV-l gp41. VII International conference on AIDS. Florence, June 1991 [abεtract WA, 1206].
(19) Weinhold KJ, Medrick HL, PLace CA, and Sebaεtian NW: Cell-mediated cytolytic reactivitieε against epitopes contained within the V3 region of HIV-l gpl20. J Cell Biochem 1990; Supplement 14D; pg 180; abs. L 550.
(20) Siliciano RF, Lawton T, Knall C, Karr RW, Berman P, Tregory T. and REingerz EL: Analysis of hoεt-viruε interactionε in AIDS with anti-gpl20 T cell clones: Effect of HIV sequence variation and a mechanism for CD4+ cell depletion. Cell 1988; 54: 561-575.
(21) Hammond SA, Obah E, Stanhope P, Monell CR, Strand M, Robbins FM, Bias WB, Karr RW, Koenig S, and Siliciano RF: Characterization of a conserved T cell epitope in HIV-l gp41 recognized by vaccine induced human cytolytic T cells. J Immunol 1991; 146: 1470-1477.
I claim:

Claims

1. A suεtained-release device comprising, a solid, immunogenic, implant that induces when implanted subcutaneouεly the formation of a εubcutaneouε, fibrouε capsule defining a chronic, inflammatory site, the implant containing an antigen asεociated with a pathogen and the implant conεtructed and arranged to present the antigen for at least two months at a level appropriate for stimulating cell-mediated immunity but at a level that doeε not induce tolerance.
2. A εuεtained-releaεe device aε claimed in claim 1 wherein the implant iε free of materialε that εuppreεs the immune responεe.
3. A sustained-release device as claimed in claim 1 wherein the implant contains an agent for εuppreεεing the converεion of macrophageε into foam cellε, the implant being constructed and arranged to deliver the agent for at leaεt two months.
4. A sustained-release device as claimed in claim 1 wherein the implant contains an antioxidant for suppresεing the conversion of macrophages into foam cells, the implant being constructed and arranged to deliver the antioxidant for at least two months.
5. A sustained-release device aε claimed in claim 1 wherein the implant contains a cytokine for stimulating cell-mediated immunity, the implant being constructed and arranged to deliver the cytokine for at least two months.
6. A suεtained-releaεe device aε claimed in claim 5 wherein the cytokine iε Interleukin-2 and Interleukin-12.
7. A suεtained-releaεe device as claimed in claim 5 wherein the implant containε an antioxidant for εuppressing the converεion of macrophages into foam cells, the implant being conεtructed and arranged to deliver the antioxidant for at leaεt two monthε.
8. A εuεtained-releaεe device as claimed in any one of claims 1-7 wherein the antigen is associated with a pathogen selected from the group consisting of: human immunodeficiency virus, cytomegalovirus, Epstein Barr virus, Hepatisis viruε, Herpeε viruε, Influenza, Human pampalloma viruε, mycobacteria, Pneumocystis carinii, Cryptococcuε neoformans, Candida and mycoplasma.
9. A εustained-release device as claimed in claims 1, 2, 3, 4, 5, 6 or 7 wherein the antigen is associated with human immunodeficiency virus.
10. A sustained-release device as claimed in claims 1, 2, 3, 4, 5, 6 or 7 wherein the implant includes a melted and recrystallized carrier and the antigen is captured in a crystalline matrix of the melted and recrystallized carrier.
11. A sustained-release device as claimed in claims 1, 2, 3, 4, 5, 6 or 7 wherein the antigen iε a peptide.
12. A method for stimulating cell-mediated immunity in a subject comprising: inducing by implanting a foreign body in the subject the formation of a subcutaneouε fibrous capsule defining a chronic, local inflammatory site, and presenting continuously for at least two months to εaid εite an antigen associated with a pathogen at a dose appropriate for stimulating cell-mediated immunity but at a dose that does not induce tolerance.
13. A method as claimed in claim 12 further compriεing delivering continuously for at least two months to said site an agent for suppressing the conversion of macrophages to foam cells.
14. A method aε claimed in claim 13 further comprising delivering continuously for at least two months to said site an antioxidant for suppressing the conversion of macrophages to foam cells.
15. A method as claimed in claim 12 further compriεing delivering continuouεly for at leaεt two monthε to said site a cytokine for εtimulating cell-mediated immunity.
16. A method aε claimed in claim 15, further comprising delivering continuously for at least two months to said site an agent for suppressing the conversion of macrophages to foam cells.
17. A method as claimed in claim 12, 13, 14, 15, or 16 wherein the antigen is associated with a pathogen selected from the group consisting of: human immunodeficiency virus, cytomegaloviruε, Epεtein Barr virus, Hepatisis virus, Herpes virus, Influenza, Human pampalloma virus, mycobacteria, Pneumocystis carinii, Cryptococcus neoformans, Candida and mycoplasma.
18. A method aε claimed in claim 12, 13, 14, 15, or 16 wherein the antigen iε asεociated with human immunodeficiency viruε.
19. A method aε claimed in claim 12, 13, 14, 15, or 16 further comprising removing cells from the subject to identify a subject-specific immuno-dominant peptide asεociated with εaid pathogen and wherein said antigen is said subject-specific immuno-dominant peptide.
PCT/US1994/006394 1993-06-07 1994-06-07 Implant stimulated cellular immunity WO1994028871A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU71012/94A AU7101294A (en) 1993-06-07 1994-06-07 Implant stimulated cellular immunity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7271893A 1993-06-07 1993-06-07
US08/072,718 1993-06-07

Publications (1)

Publication Number Publication Date
WO1994028871A1 true WO1994028871A1 (en) 1994-12-22

Family

ID=22109334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/006394 WO1994028871A1 (en) 1993-06-07 1994-06-07 Implant stimulated cellular immunity

Country Status (2)

Country Link
AU (1) AU7101294A (en)
WO (1) WO1994028871A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012809A2 (en) * 1994-10-20 1996-05-02 Institut Pasteur Nucleotide sequences of hiv-1 type (or subtype) o retrovirus antigens
FR2731225A1 (en) * 1995-03-03 1996-09-06 Pasteur Institut New antigenic HIV-1 group O strain proteins and related nucleic acids
WO1999013095A2 (en) * 1997-09-11 1999-03-18 The Johns Hopkins University School Of Medicine Use of multivalent chimeric peptide-loaded, mhc/ig molecules to detect, activate or suppress antigen-specific t cell-dependent immune responses
WO1999051750A1 (en) * 1998-04-03 1999-10-14 Glaxo Group Limited Medicaments for inducing cytotoxic t-cells
WO2000052040A1 (en) * 1999-03-04 2000-09-08 Bionor Immuno As Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
US6448071B1 (en) 1996-03-28 2002-09-10 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
EP1307130A4 (en) * 2000-02-04 2005-01-12 Beth Israel Hospital Human immunodeficiency virus vaccine
WO2005097822A1 (en) * 2004-04-09 2005-10-20 University Of Manitoba Identification of the precise amino acid sequence of the epitope recognized by the potent neutralizing human anti-hiv-1 monoclonal antibody igg1b12
WO2007028219A1 (en) 2005-09-05 2007-03-15 Fundacão De Amparo À Pesquisa Do Estado De São Paulo Epitopes, combined epitopes, use of epitopes or their combination, composition, uses of the composition, anti- hiv-i prophylactic vaccines, therapeutic vaccines, method for the identification of epitopes and methods for treatment and prevention
EP3515438A4 (en) * 2016-09-21 2020-06-03 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011030A1 (en) * 1990-12-19 1992-07-09 Schering Corporation Use of il-4 to enhance immune response to immunogens in vaccines
WO1992020325A1 (en) * 1991-05-14 1992-11-26 Endocon, Inc. Engineering the local inflammatory response as a means of controlled release drug delivery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992011030A1 (en) * 1990-12-19 1992-07-09 Schering Corporation Use of il-4 to enhance immune response to immunogens in vaccines
WO1992020325A1 (en) * 1991-05-14 1992-11-26 Endocon, Inc. Engineering the local inflammatory response as a means of controlled release drug delivery

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012809A2 (en) * 1994-10-20 1996-05-02 Institut Pasteur Nucleotide sequences of hiv-1 type (or subtype) o retrovirus antigens
WO1996012809A3 (en) * 1994-10-20 1996-06-20 Pasteur Institut Nucleotide sequences of hiv-1 type (or subtype) o retrovirus antigens
US8236324B2 (en) 1994-10-20 2012-08-07 Institut Pasteur Nucleotide sequences of HIV-1 group (or subgroup) O retroviral antigens
US7157225B2 (en) 1994-10-20 2007-01-02 Institut Pasteur Nucleotide sequences of HIV-1 type (or subtype) O retrovirus antigens
US6399294B1 (en) 1994-10-20 2002-06-04 Institut Pasteur Nucleotide sequences of HIV-1 type (or subtype) O retrovirus antigens
FR2731225A1 (en) * 1995-03-03 1996-09-06 Pasteur Institut New antigenic HIV-1 group O strain proteins and related nucleic acids
US6448071B1 (en) 1996-03-28 2002-09-10 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6734013B2 (en) 1997-03-28 2004-05-11 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/Ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
WO1999013095A3 (en) * 1997-09-11 1999-06-10 Univ Johns Hopkins Med Use of multivalent chimeric peptide-loaded, mhc/ig molecules to detect, activate or suppress antigen-specific t cell-dependent immune responses
WO1999013095A2 (en) * 1997-09-11 1999-03-18 The Johns Hopkins University School Of Medicine Use of multivalent chimeric peptide-loaded, mhc/ig molecules to detect, activate or suppress antigen-specific t cell-dependent immune responses
WO1999051750A1 (en) * 1998-04-03 1999-10-14 Glaxo Group Limited Medicaments for inducing cytotoxic t-cells
WO2000052040A1 (en) * 1999-03-04 2000-09-08 Bionor Immuno As Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv
US7311915B2 (en) 1999-03-04 2007-12-25 Bionor A/S Method of producing an HIV-1 immune response
CZ300505B6 (en) * 1999-03-04 2009-06-03 Bionor Immuno As Vaccine preparation
US7709004B2 (en) 1999-03-04 2010-05-04 Bionor Immuno As Method of producing an HIV-1 immune response
US7709003B2 (en) 1999-03-04 2010-05-04 Bionor Immuno As Method of producing an HIV-1 immune response
US6706859B1 (en) 1999-03-04 2004-03-16 Bionor Immuno As HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
EA004802B9 (en) * 1999-03-04 2015-03-31 Бионор Иммуно Ас This empty document was created automatically and should be filled up and updated.
EP1307130A4 (en) * 2000-02-04 2005-01-12 Beth Israel Hospital Human immunodeficiency virus vaccine
WO2005097822A1 (en) * 2004-04-09 2005-10-20 University Of Manitoba Identification of the precise amino acid sequence of the epitope recognized by the potent neutralizing human anti-hiv-1 monoclonal antibody igg1b12
WO2007028219A1 (en) 2005-09-05 2007-03-15 Fundacão De Amparo À Pesquisa Do Estado De São Paulo Epitopes, combined epitopes, use of epitopes or their combination, composition, uses of the composition, anti- hiv-i prophylactic vaccines, therapeutic vaccines, method for the identification of epitopes and methods for treatment and prevention
EP1937711A1 (en) * 2005-09-05 2008-07-02 Fundacão de Amparo à Pesquisa do Estado de São Paulo Epitopes, combined epitopes, use of epitopes or their combination, composition, uses of the composition, anti- hiv-i prophylactic vaccines, therapeutic vaccines, method for the identification of epitopes and methods for treatment and prevention
EP1937711A4 (en) * 2005-09-05 2009-07-01 Fundacao De Amparo A Pesquisa Epitopes, combined epitopes, use of epitopes or their combination, composition, uses of the composition, anti- hiv-i prophylactic vaccines, therapeutic vaccines, method for the identification of epitopes and methods for treatment and prevention
EP3515438A4 (en) * 2016-09-21 2020-06-03 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors

Also Published As

Publication number Publication date
AU7101294A (en) 1995-01-03

Similar Documents

Publication Publication Date Title
McBride et al. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity
Gazzinelli et al. Parasite-induced IL-12 stimulates early IFN-gamma synthesis and resistance during acute infection with Toxoplasma gondii.
Donnelly et al. Technical and regulatory hurdles for DNA vaccines
Kataoka et al. Nasal Flt3 ligand cDNA elicits CD11c+ CD8+ dendritic cells for enhanced mucosal immunity
WO1994028871A1 (en) Implant stimulated cellular immunity
AU758622B2 (en) Method for activating natural killer (NK) cells
Kaplan et al. The role of cytokines in the immune response to tuberculosis
Jo Wick et al. Processing of bacterial antigens for peptide presentation on MHC class I molecules
JP2011036251A (en) Virus vector, and use of the same for gene therapy
CN100425287C (en) Tumor vaccines
Qing et al. Construction of an HBV DNA vaccine by fusion of the GM-CSF gene to the HBV-S gene and examination of its immune effects in normal and HBV-transgenic mice
AU2008348260A1 (en) Immunomodulating compositions and uses therefor
Kubota et al. Oral immunization with simian immunodeficiency virus p55gag and cholera toxin elicits both mucosal IgA and systemic IgG immune responses in nonhuman primates.
Kawakami et al. NK cells eliminate Cryptococcus neoformans by potentiating the fungicidal activity of macrophages rather than by directly killing them upon stimulation with IL-12 and IL-18
KR101300905B1 (en) Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
Stevenson et al. Modulation of host responses to blood-stage malaria by interleukin-12: from therapyto adjuvant activity
EP1843787B1 (en) Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
Johnson-Weaver et al. Nasal immunization with small molecule mast cell activators enhance immunity to Co-administered subunit immunogens
KR100773390B1 (en) Herpes Simplex virus vaccine kit
US20030087846A1 (en) Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
Alvarez et al. In vitro restoration of Th17 response during HIV infection with an antiretroviral drug and Th17 differentiation cytokines
CA2454920C (en) Antigenic compositions
CN1639569B (en) Methods and compositions for inducing an immune response
US20070275071A1 (en) Use of Microparticles for Antigen Delivery
US20040146486A1 (en) Hybrid vector system for use as a vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA